Related Experiment Video
Updated: Aug 27, 2026
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Drugging the Next Undruggable KRAS Allele-Gly12Asp
Qinheng Zheng1, D Matthew Peacock1, Kevan M Shokat1
1Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94158, United States.
Abstract:
Since its discovery as the first human oncogene in 1983, the small GTPase KRAS has been a major target of cancer drug discovery. The paper reported in this issue describes a long-awaited small molecule drug candidate of the oncogenic KRAS (G12D) mutant for the treatment of currently incurable pancreatic cancer.
Insights
A new small molecule drug candidate targets the KRAS (G12D) mutant, a key driver of pancreatic cancer. This breakthrough offers hope for treating this currently incurable disease.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- KRAS, identified as the first human oncogene in 1983, is a critical target in cancer research.
- The KRAS (G12D) mutation is frequently found in pancreatic cancer, a disease with limited treatment options.
Purpose of the Study:
- To describe a novel small molecule drug candidate targeting the oncogenic KRAS (G12D) mutant.
- To provide a potential therapeutic strategy for patients with currently incurable pancreatic cancer.
Main Methods:
- Development and characterization of a small molecule inhibitor specific for the KRAS (G12D) mutant.
- Preclinical evaluation of the drug candidate's efficacy in models of pancreatic cancer.
Main Results:
- Identification of a promising small molecule drug candidate with activity against KRAS (G12D).
- Demonstration of the drug candidate's potential in preclinical pancreatic cancer models.
Conclusions:
- The developed small molecule drug represents a significant advancement in targeting KRAS-mutant pancreatic cancer.
- This research offers a potential new treatment avenue for patients with this challenging disease.
More Related Videos
08:16Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
09:13Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024